Is osimertinib a domestic drug or an imported drug?

Osimertinib, also known asOsimertinib, its trade name is Tagrisso, is a very important targeted therapy drug. This drug is produced by the British company AstraZeneca and is an imported drug. In China, it has been approved for import by the Food and Drug Administration and is widely known under the Chinese trade name Tagrisso.

Osimertinib is a third-generation TKI targeted drug. It is oral and irreversible. It is a tyrosine kinase inhibitor of EGFR (epidermal growth factor receptor). Clinically, it has shown significant therapeutic effects, especially for patients with advanced non-small cell lung cancer (NSCLC) harboring the T790M gene mutation. This gene mutation often occurs in patients who develop drug resistance after long-term use of drugs such as Iressa, Kemena or Tarceva. The emergence of osimertinib provides new treatment opportunities for these patients.

In addition to its potent inhibitory effect on T790M mutated cancer cells, osimertinib has relatively mild side effects, mainly manifesting as skin rash, nail discoloration, and diarrhea. The drug is taken orally at a dose of 80 mg once daily until disease progression or unacceptable side effects occur. It is worth mentioning that the efficacy of osimertinib is not affected by food, but it is recommended to swallow the tablet whole with water to maintain the stability of the efficacy.

Although osimertinib is an imported drug, it is widely recognized and used globally, including in China. For many patients with advanced non-small cell lung cancer, the drug not only extends their survival but also improves their quality of life. However, as a powerful drug, osimertinib still needs to be used with caution and in strict accordance with the doctor's instructions to ensure patient safety and therapeutic effect.

Overall, osimertinib, as an imported targeted therapy drug, provides new hope and treatment options for patients with non-small cell lung cancer, especially those who are resistant to traditional treatments.